Talazoparib

About

Therapy type: Targeted therapy

Therapy strategy: PARP inhibition

Mappings

NCI Thesaurus: Talazoparib (coding:ncit:C95733)

RxNorm: talazoparib (coding:rxcui:2099704, coding:omop:35201068)

SNOMED: Talazoparib (coding:sctid:782199007, coding:omop:36684109)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations	Biomarkers	Cancer types	Therapies
FDA (1) HC (1)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1)	RAD51B oncogenic variants	Prostate Adenocarcinoma	Talazoparib
FDA (1) HC (1)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
FDA (1) HC (1)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
FDA (1) HC (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	ATM pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	ATM oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	ATR oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	CDK12 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	ATR pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	FANCA oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	FANCA pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	MLH1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	PALB2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	PALB2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	MLH1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	MRE11 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	RAD51C pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	RAD51C oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	MRE11 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	NBN oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1) HC (1)	NBN pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
FDA (1)	CDK12 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib